Exciting Developments Unveiled in Recursion's Webinar
Recursion, a forefront player in the TechBio space, is poised to share groundbreaking insights from their ongoing clinical trial. The TUPELO Phase 1b/2 trial focuses on REC-4881, designed specifically for families affected by Familial Adenomatous Polyposis (FAP). This webinar, scheduled for December 8, 2025, promises to showcase invaluable data related to this innovative treatment.
Understanding the Webinar Details
The upcoming event will commence at 8:00 am ET, providing a platform for industry experts to elaborate on the significant findings derived from the clinical study. Live streaming will occur across various platforms, including Recursion’s X, LinkedIn, and YouTube channels, ensuring comprehensive accessibility for interested participants.
Webinar Overview and Presentation
The title of the webinar—"Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy"—offers a clear indication of the critical insights to be shared. Presenters for this informative session include:
- Najat Khan, Ph.D, Chief R&D and Chief Commercial Officer, along with an exciting new leadership role as incoming CEO and President at Recursion.
- David Mauro, M.D., Ph.D, who serves as the Chief Medical Officer, providing rich insights into the clinical ramifications of FAP treatments.
- Beth Bruckheimer, Ph.D, Vice President of Clinical Development, contributing her expertise on the development landscape.
- Jessica Stout, D.O, Assistant Clinical Professor at the University of Utah School of Medicine, presenting a well-rounded perspective.
- Alfred Cohen, M.D, Former CMO of Cancer Prevention Pharmaceuticals, who brings considerable experience from his background.
A Deep Dive into Recursion’s Mission
Founded with the mission to radically improve lives through biology, Recursion (NASDAQ: RXRX) operates as a clinical stage TechBio company. Their proprietary Recursion OS platform merges advanced technologies, resulting in one of the largest biological and chemical datasets globally. This unique status allows them to apply sophisticated machine-learning algorithms that filter through trillions of potential relationships, simplifying complex biological and chemical interactions.
The Foundation of Innovation in Medicine
By conducting millions of wet lab experiments weekly, Recursion is at the cutting edge of drug discovery and development. Their operational magnitude is supported by one of the most powerful supercomputers available, enabling remarkable advancements in the realm of medicine. This unique combination of technology and biological understanding aims to pave the way for new and effective therapies that could change lives.
Connecting with Recursion's Vision
Headquartered in Salt Lake City, Recursion is a proud member of BioHive, the lifesciences industry collective in Utah. The company extends its influence across various cities, including an international presence in Montréal, New York, London, and in the Oxford area. These extensive operations reflect their commitment to innovation and growth within the biopharmaceutical sector.
For those interested in learning more about Recursion’s mission and innovative approaches, visit www.recursion.com. Stay engaged with their progress on X and LinkedIn.
Frequently Asked Questions
What is the focus of Recursion's webinar?
The webinar centers around the TUPELO Phase 1b/2 trial of REC-4881, focusing on its implications for Familial Adenomatous Polyposis.
Who are the key presenters in the webinar?
Presenters include Najat Khan, David Mauro, Beth Bruckheimer, Jessica Stout, and Alfred Cohen, who will provide insights into the latest findings.
When will the webinar take place?
The webinar is scheduled for December 8, 2025, at 8:00 am ET.
How can viewers access the webinar?
The webinar will be streamed live on Recursion's X, LinkedIn, and YouTube channels for easy access.
What is the mission of Recursion?
Recursion aims to decode biology through innovative technology to improve lives significantly, showcasing their role in advancing medical treatments.
